SCHEMBL24721069

SCHEMBL24721069

CC(C)c1cccc(-c2ccc(-c3nccs3)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.54
LOXL2 Q9Y4K0 1/20 0.49
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48
ADRB2 P07550 2/20 0.45
CYP2A6 P11509 1/20 0.45
CTSA P10619 6/20 0.45
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
PTPN5 P54829 2/20 0.42
KCNB1 Q14721 3/20 0.41
KDR P35968 1/20 0.40
KCNA5 P22460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13801391 0.92 PDPK1 (0.55) PDPK1LOXL2RXRARXRBRXRG
SCHEMBL11994379 0.82 PDPK1 (0.57) PDPK1LOXL2ADRB2CYP2A6SLC6A4
SCHEMBL29793545 0.80 PDPK1 (0.51) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL27992983 0.80 PDPK1 (0.51) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL28405984 0.80 PDPK1 (0.51) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL5888543 0.80 PDPK1 (0.51) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL23601602 0.80 PDPK1 (0.59) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL24227164 0.78 PDPK1 (0.49) PDPK1LOXL2ADRB2CYP2A6CTSA
SCHEMBL5147639 0.76 PDPK1 (0.91) PDPK1LOXL2ADRB2CYP2A6SLC6A4
SCHEMBL598181 0.76 RXRA (0.66) RXRARXRBRXRGPTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK PDPK1 8/4885LOXL2 1787/4885RXRA 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.